drugset / Trial / NCT01070030

Efficacy and Safety of Combination Therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Stage II Hypertension

NCT01070030

Phase 4 Completed 230 enrolled Novartis
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study assessed the efficacy and safety of combination therapy of Aliskiren/Amlodipine or Aliskiren/Amlodipine/Hydrochlorothiazide in patients with stage II Hypertension.

Timeline

Start
2010-01
Primary completion
2010-10
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg
Subject Amlodipine Other / unclassified 10 mg
Subject Hydrochlorothiazide Unknown 25 mg
Background Atenolol Other / unclassified 50 mg

Indications